thumbnail image
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
    • PRESS RELEASES

      Archive

      twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates

      November 13, 2020

      twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311

      June 22, 2020

      Howard Rosen Joins twoXAR Pharmaceuticals' Board of Directors

      June 3, 2020

      twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel Lupus Drug Leads

      April 21, 2020

      twoXAR Pharmaceuticals Announces Appointment of Mark Eller, Ph.D. as Senior Vice President of Research and Development and Anjali Pandey, Ph.D. as Senior Vice President of Nonclinical R&D and Chemistry

      March 3, 2020

      1ST Biotherapeutics and twoXAR Advance Three Novel Glioblastoma Treatment Candidates into In Vivo Testing in Less Than One Year

      February 25, 2020

    • BLOG

      This Year's JPM Conference Should Give Our Industry Confidence ​

      Andrew A. Radin, twoXAR CEO

      January 21, 2021

      Every year, for the past 39 years, the J.P. Morgan Healthcare Conference has been one of the most reliable predictors of our industry’s health. It’s a gauge of industry innovation, deal making, funding and overall sentiment about the value of the pharmaceutical market.

      However, this year was obviously different. We were faced with unprecedented economic decline and an industry seemingly entirely focused on COVID-19. Expectations were tempered for a lot of companies as to what impact this pandemic and this economy will have on funding new pharmaceutical innovation..read post here.

      Looking forward to 2021 at twoXAR

      Andrew A. Radin, twoXAR CEO

      December 16, 2020

      Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. And despite all of its tragic outcomes, it has starkly reminded me that we work in one of the most exciting and innovative industries in the world — the life sciences industry.

      I am writing this at a time when the US FDA has just issued an emergency use authorization for a vaccine using new technology, against a new pathogen. We are also just days away from another potential FDA vaccine approval. All of this happened in only a few months and it’s remarkable. Although we do not work in vaccines or pathogenic diseases, and I’ve discussed why in a recent post, I feel more energized than ever to be a part of an industry that can make this happen...read post here.

      Why twoXAR Pharmaceuticals isn't working on COVID-19

      Andrew A. Radin, twoXAR CEO

      October 28, 2020

      I recently authored an article for MedCity News discussing the hype surrounding AI, especially as it relates to fighting COVID-19. Since the very beginning of this pandemic, researchers and pharmaceutical companies have been working around the clock to find treatments and, more importantly, develop a vaccine. And, as usual, there has been a plethora of media articles and peer-reviewed journal publications discussing how AI can support these efforts. A lot of that is driven by AI companies themselves, or companies that apply AI to discover treatments...read post here.

      Sprinting our way to 250

      Aaron Daugherty, VP Discovery

      March 10, 2020

      This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.

       

      Our platform makes drug discovery and development faster and with fewer false positives. To build this platform, we use an approach that tightly couples scientists and software developers to make R&D faster, more accurate, and/or cheaper...read post here.

      twoXAR Pharmaceuticals Announces Appointment of Timothy Heuer, PhD as Fellow​

      Andrew A. Radin, twoXAR CEO

      February 18, 2020

      I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then identifies hits to test those new hypotheses within weeks instead of years. I’ve come to learn that the furrowed brow appears when the gears start turning in Tim’s head. And what exceptional gears they are... read post here.

      It’s Like Nothing Else​

      Andrew A. Radin, twoXAR CEO

      February 3, 2020

      Today I received an email from an influencer in the life science community. Paraphrasing a bit, here’s what she said:

       

      “We have reviewed nearly 400 companies in this space — so much going on! How are you differentiated from others?”

       

      Rather than email her individually, I viewed this as the perfect opportunity to share how twoXAR Pharmaceuticals is different. Our work is like nothing else... read post here.

    • Read full blog at: twoxar.medium.com

    • EVENTS

      Archive

      Innovation in Drug Research and Development for Chronic Diseases - Part 1

      National Academies of Science, Engineering, and Medicine (Virtual)

      February 22, 2021

      twoXAR Pharmaceuticals CEO Andrew A. Radin presents in a session on new technologies enabling discovery research.

      2021 MIT ILP WuXi Virtual Symposium

      MIT ILP (Digital)

      January 27, 2021

      twoXAR Pharmaceuticals CEO Andrew Radin presents at the MIT Startup Exchange Lightning Talk.

       

      Biotech Showcase

      Digital

      January 11-15, 2021

      twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.

      Using Artificial Intelligence in Drug Discovery

      CM Life Sciences (Digital)

      December 3, 2020

      twoXAR Pharmaceuticals CEO Andrew A. Radin joins a webinar hosted by CM Life Sciences to discuss harnessing AI in drug discovery.

       

      On Demand Video

      EPPIC Global Presents: Role of AI/ML in transforming and accelerating the drug discovery process

      EPPIC Global (Digital)

      October 17, 2020

      twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.

       

      MIT ILP: Precision Medicine in Oncology

      MIT ILP (Digital)

      October 16, 2020

      twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules for oncology and more using AI.

    • FEATURE ARTICLES

      Archive

      Will COVID-19 be the straw that breaks AI's back?

      Andrew Radin

      MedCity News

      October 21, 2020

      AI in the Life Sciences 2020

      Global Business Reports
      October 1, 2020

      Xconomy XLS Special Report: The AI, Big Data, and R&D Boom

      Xconomy Special Report
      August 27, 2020

      Code for Cures: Life Sciences Thrives on San Francisco's Software Heritage

      Xconomy

      June 30, 2020

      TXR-311 Shows Promising Preclinical Efficacy and Safety in Hepatocellular Carcinoma​

      Targeted Oncology

      June 26, 2020

      AACR 2020: Positive Preclinical Safety & Efficacy Data for TXR-311 in HCC

       

      OncoZine

      June 22, 2020

    • MEDIA MENTIONS

      Archive

      AI in the Life Sciences: 2020

      Global Business Reports

      September 2020

      AI 50: America's Most Promising Artificial Intelligence Companies

      Forbes

      July 3, 2020

      Frost & Sullivan Names Top Innovators in Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry

      Frost & Sullivan

      June 9, 2020

      Two leads for the potential treatment of systemic lupus erythematosus demonstrated significant efficacy and excellent tolerability in preclinical studies

      BioWorld

      April 21, 2020

       

      1ST Biotherapeutics and twoXAR advance three novel glioblastoma treatment candidates

      DDNews

      March 2020

      AI-Driven twoXAR and Ono Pharma Collaborate on Drug Discovery Research

      PharmaVOICE

      May 2019

    • Andrew A. Radin, CEO - TEDMED 2016

    • WEBINARS, PODCASTS & VIDEOS

      Archive

      Webinar Series Part 3

      twoXAR Tutorials

      December 2, 2020

      SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR

      Webinar Series Part 2

      twoXAR Tutorials

      December 2, 2020

      VP Discovery, Aaron Daugherty shares how we collaborate with our partners

      Webinar Series Part 1

      twoXAR Tutorials

      December 2, 2020

      SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem

      Podcast: Moneyball Medicine

      The Moneyball Medicine Podcast

      September 14, 2020

      twoXAR Pharmaceuticals SVP of R&D Mark Eller, Ph.D. joins host Harry Glorikian to discuss his journey from traditional pharma to believing in the power of AI.

      Podcast: Moneyball Medicine

      The Moneyball Medicine Podcast

      August 31, 2020

      twoXAR Pharmaceuticals CEO Andrew A. Radin joins host Harry Glorikian to discuss the latest updates from twoXAR Pharmaceuticals.

      Video: Oncology Tube Part 1

      Video Oncology Tube Part 2

      Oncology Tube

      August 28, 2020

      twoXAR Fellow, Dr. Timothy Heuer discusses twoXAR's investigational cancer treatment TXR-311.

    • PUBLICATIONS & POSTERS

      Poster: Preclinical identification and development of small molecule drug discovery leads with novel MOAs for non-alcoholic steatohepatitis (NASH)

      Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer

       

      Download Poster (PDF)

      Poster: Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma

      Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer

       

      Download Abstract

      Download Poster (PDF)

      Download Audio

      Abstract: Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)​

      Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

      Poster: Computational discovery and preclinical validation of therapeutic leads with novel MOAs for systemic lupus erythematosus (SLE)​

      Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer

       

      Download Abstract (PDF)

      Download Poster (PDF)

      Synergistic drug combinations from electronic health records and gene expression

      Yen S Low, Aaron C Daugherty, Elizabeth A Schroeder, William Chen, Tina Seto, Susan Weber, Michael Lim, Trevor Hastie, Maya Mathur, Manisha Desai, Carl Farrington, Andrew A Radin, Marina Sirota, Pragati Kenkare, Caroline A Thompson, Peter P Yu, Scarlett L Gomez, George W Sledge Jr, Allison W Kurian, Nigam H Shah. Journal of the American Medical Informatics Association. EPub: December 9, 2016​

      Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform​

      Aaron C Daugherty, Carl Farrington, Isaac Hakin, Sana Mujahid, Elizabeth S Noblin, Andrew M Radin, Mei-Sze Chua, Mark Rabe, Guy Fernald, Daniel Ford, Marina Sirota, Laura Schaevitz, Andrew A Radin. bioRxiv 243998; doi: https://doi.org/10.1101/243998

      Poster: An Integrative Bioinformatics Approach Identifies In Vivo Validated Drug Candidates with Novel Mechanisms of Action in Rheumatoid Arthritis​​

      Aaron C Daugherty1, Carl Farrington1, Isaac Hakim1, Elizabeth S Noblin1, Andrew M Radin1, Mei-Sze Chua2, Mark Rabe3, Guy Fernald3, Daniel Ford3, Marina Sirota4, Laura Schaevitz3, Andrew A Radin1

      1twoXAR, 2Stanford University School of Medicine, 3Vium, 4UCSF

       

      Download Poster (PDF)

      Download Supplementary Material (PDF)

    © 2021 twoXAR, Incorporated | All Rights Reserved

      Home
      Pipeline
      News
      Contact
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More